Novomix 30 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 30 Flexpen, is an insulin analog presented as a solution for injection (prefilled pen) for subcutaneous use. It is indicated for the management of blood glucose in both type 1 and type 2 diabetes mellitus across pediatric and adult populations, providing rapid‑acting insulin to cover post‑prandial glucose excursions.

GNH USA supplies Novomix 30 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for temperature‑sensitive products.

Novomix 30 Flexpen, an insulin analog, is used in the management of diabetes mellitus to control blood glucose levels.

Type 1 diabetes mellitus: provides rapid‑acting insulin to control post‑prandial glucose spikes. Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve glycaemic targets. Adjunct to diet and exercise in diabetes: helps maintain overall blood glucose control when oral agents are insufficient.

Like other rapid‑acting insulins, Novomix 30 Flexpen may be associated with a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood‑sugar episodes, especially if meals are missed or delayed. - Injection‑site pain or erythema: mild discomfort or redness at the injection site. - Weight gain: modest increase in body weight with prolonged use.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare allergic response with rash, swelling or breathing difficulty. - Lipodystrophy: abnormal fat distribution at repeated injection sites.

When using Novomix 30 Flexpen, several precautions should be observed to ensure safe and effective therapy.

Monitor blood glucose: adjust dose based on readings and meals. Avoid use during active hypoglycaemia: do not administer if glucose is already low. Pregnancy category B: use only if benefits outweigh potential risks. Renal or hepatic impairment: dose may need adjustment and close monitoring. Do not share pen: risk of cross‑contamination and dosing errors. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin aspart can interact with several medicines, altering its glucose‑lowering effect or masking hypoglycaemia.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of hypoglycaemia. - MAO inhibitors: can potentiate insulin’s hypoglycaemic action. - Alcohol excess: increases risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Thiazolidinediones: may increase insulin requirement. - Diuretics: can affect potassium balance and glucose control. - Corticosteroids: may raise blood glucose, requiring dose adjustment.